Stock listing
NASDAQ:MSLE Satellos Bioscience Inc Stock
US listing (NASDAQ) of Satellos Bioscience Inc · home listing TSX:MSCL
Follow Satellos Bioscience Inc into a list and get an email when it puts out news.
Share price · NASDAQ:MSLE
$5.68 USD -0.12 (-2.1%)
Close on Nov 20, 2026
- Day range
- $5.62 – $6.00 USDNov 20, 2026
- Volume
- 113,907 sharesNov 20, 2026
- Market cap
- $120.5M USDAt the close on Nov 20, 2026 · price × 21.22M shares outstanding
- 52-week range
- $5.44 – $13.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $400,994 USDMedian day 29,600 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:MSCL · Home | $8.24 CAD | -0.38 (-4.4%) | 13,796 | $8.50 | $8.50 | $8.11 | $8.62 | Close on Nov 20, 2026 |
| NASDAQ:MSLE | $5.68 USD | -0.12 (-2.1%) | 113,907 | $5.71 | $6.001 | $5.62 | $5.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · NASDAQ:MSLE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.19 | +0.84 | +13.2% | $6.57 | $7.50 | $6.42 | 290,700 | |
| $6.35 | -0.12 | -1.9% | $6.50 | $6.55 | $6.10 | 124,800 | |
| $6.47 | +0.10 | +1.6% | $6.55 | $6.65 | $6.39 | 11,700 | |
| $6.37 | -0.03 | -0.5% | $6.39 | $6.52 | $6.37 | 14,500 | |
| $6.40 | -0.30 | -4.5% | $6.75 | $6.75 | $6.40 | 3,100 | |
| $6.70 | -0.115 | -1.7% | $6.675 | $6.93 | $6.43 | 30,800 | |
| $6.815 | +0.315 | +4.8% | $6.50 | $7.00 | $6.36 | 33,000 | |
| $6.50 | -0.38 | -5.5% | $6.763 | $7.11 | $6.44 | 82,600 | |
| $6.88 | +0.34 | +5.2% | $6.59 | $7.19 | $6.51 | 22,200 | |
| $6.54 | +0.12 | +1.9% | $6.42 | $6.70 | $6.26 | 56,700 | |
| $6.42 | -0.205 | -3.1% | $6.53 | $6.725 | $6.42 | 33,700 | |
| $6.625 | -0.075 | -1.1% | $6.744 | $6.95 | $6.565 | 21,300 | |
| $6.70 | -0.30 | -4.3% | $6.94 | $7.12 | $6.61 | 28,300 | |
| $7.00 | +0.56 | +8.7% | $6.39 | $7.025 | $6.39 | 13,500 | |
| $6.44 | -0.02 | -0.3% | $6.54 | $7.00 | $6.35 | 29,400 | |
| $6.46 | -0.38 | -5.6% | $6.75 | $6.86 | $6.40 | 13,300 | |
| $6.84 | +0.21 | +3.2% | $6.68 | $7.06 | $6.515 | 79,900 | |
| $6.63 | -0.41 | -5.8% | $7.14 | $7.14 | $6.51 | 43,800 | |
| $7.04 | -0.13 | -1.8% | $7.16 | $7.45 | $6.88 | 92,900 | |
| $7.17 | -0.32 | -4.3% | $7.58 | $7.58 | $7.065 | 66,000 | |
| $7.49 | +0.145 | +2.0% | $7.30 | $7.74 | $7.29 | 59,900 | |
| $7.345 | -0.285 | -3.7% | $8.08 | $8.08 | $7.25 | 121,400 | |
| $7.63 | +0.09 | +1.2% | $7.70 | $8.35 | $7.44 | 47,700 | |
| $7.54 | -0.51 | -6.3% | $8.08 | $8.381 | $7.54 | 48,100 | |
| $8.05 | -0.45 | -5.3% | $8.46 | $8.60 | $8.05 | 24,800 | |
| $8.50 | 0.00 | 0.0% | $8.56 | $8.73 | $8.325 | 27,700 | |
| $8.50 | 0.00 | 0.0% | $8.51 | $8.94 | $8.30 | 80,000 | |
| $8.50 | -0.10 | -1.2% | $8.60 | $8.82 | $8.45 | 89,200 | |
| $8.60 | -0.21 | -2.4% | $8.67 | $8.85 | $8.35 | 433,300 | |
| $8.81 | +0.11 | +1.3% | $8.51 | $9.03 | $8.51 | 48,100 | |
| $8.70 | -0.01 | -0.1% | $8.775 | $8.86 | $8.535 | 37,400 | |
| $8.71 | +0.30 | +3.6% | $8.50 | $8.77 | $8.36 | 41,000 | |
| $8.41 | -0.46 | -5.2% | $8.84 | $8.86 | $8.41 | 43,000 | |
| $8.87 | -0.31 | -3.4% | $9.16 | $9.432 | $8.82 | 26,800 | |
| $9.18 | -0.14 | -1.5% | $9.31 | $9.47 | $9.16 | 11,944 | |
| $9.32 | -0.36 | -3.7% | $9.72 | $9.75 | $9.31 | 19,800 | |
| $9.68 | +0.38 | +4.1% | $9.27 | $9.76 | $9.27 | 17,600 | |
| $9.30 | -0.06 | -0.6% | $9.50 | $9.66 | $9.185 | 29,800 | |
| $9.36 | -0.43 | -4.4% | $9.695 | $9.695 | $9.33 | 16,900 | |
| $9.79 | +0.04 | +0.4% | $9.76 | $10.00 | $9.76 | 7,700 | |
| $9.75 | -0.30 | -3.0% | $10.13 | $10.30 | $9.44 | 33,700 | |
| $10.05 | +0.03 | +0.3% | $10.13 | $10.50 | $9.82 | 47,200 | |
| $10.02 | +0.84 | +9.2% | $9.45 | $10.47 | $9.27 | 72,600 | |
| $9.18 | +0.21 | +2.3% | $9.00 | $9.554 | $8.91 | 82,300 | |
| $8.97 | -0.11 | -1.2% | $9.125 | $9.25 | $8.95 | 25,600 | |
| $9.08 | +0.03 | +0.3% | $9.127 | $9.38 | $8.96 | 27,500 | |
| $9.05 | -0.03 | -0.3% | $9.12 | $9.20 | $8.93 | 10,700 | |
| $9.08 | -0.26 | -2.8% | $9.25 | $9.26 | $9.07 | 3,500 | |
| $9.34 | +0.68 | +7.9% | $8.78 | $9.45 | $8.68 | 53,300 | |
| $8.66 | -0.95 | -9.9% | $9.55 | $9.55 | $8.66 | 18,300 | |
| $9.61 | +0.25 | +2.7% | $9.35 | $9.61 | $9.35 | 9,000 | |
| $9.36 | -0.04 | -0.4% | $9.40 | $9.55 | $9.31 | 11,300 | |
| $9.40 | -0.07 | -0.7% | $9.55 | $9.99 | $9.34 | 27,800 | |
| $9.47 | -0.54 | -5.4% | $9.89 | $9.89 | $9.34 | 17,000 | |
| $10.01 | -0.175 | -1.7% | $10.00 | $10.16 | $9.80 | 22,100 | |
| $10.19 | +0.095 | +0.9% | $10.16 | $10.35 | $9.90 | 27,400 |
Splits
2 splits since 2021 · NASDAQ:MSLE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:MSLE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
Latest deck · Nov 6, 2026
Corporate Update (November 2026)
Corporate update · 17 slides
Latest news
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
Nov 6, 2026
Closed $7.19 (+13.2%) on Nov 6, 2026
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
Nov 5, 2026
Closed $7.19 (+13.2%) on Nov 6, 2026
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Oct 27, 2026
Closed $6.88 (+5.2%) on Oct 27, 2026
Satellos to Participate in Upcoming Investor Conferences
Oct 21, 2026
Closed $6.70 (-4.3%) on Oct 21, 2026
Satellos Granted Composition of Matter Patent for Forazapadin
Oct 5, 2026
Closed $8.05 (-5.3%) on Oct 5, 2026
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Sep 30, 2026
Closed $8.50 (-1.2%) on Sep 30, 2026
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Sep 24, 2026
Closed $8.71 (+3.6%) on Sep 24, 2026
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Sep 15, 2026
Closed $9.36 (-4.4%) on Sep 15, 2026
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Sep 9, 2026
Closed $10.02 (+9.2%) on Sep 9, 2026
Satellos Bioscience Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 122 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 17 decks · latest Nov 6, 2026
Where Satellos Bioscience Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:MSCL · Home listing | TSX | Canada | CAD |
| NASDAQ:MSLE · This page | NASDAQ | United States | USD |
| Cboe Canada:MSCL | Cboe Canada | Canada | CAD |
| LS Exchange:A4211W | LS Exchange | Germany | EUR |
| Lang & Schwarz:A4211W | Lang & Schwarz | Germany | EUR |
| BOATS:MSLE | BOATS | United States | USD |
| Frankfurt:0IT | Frankfurt | Germany | EUR |
| Stuttgart:0IT | Stuttgart | Germany | EUR |
| Tradegate:0IT | Tradegate | Germany | EUR |
Valuation
Price/book 2.5× against a median of 2.2×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $99.29M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 0.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.24M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$123.5M | US$137.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.67M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.4× | n/a | n/a | −146.4% | n/a | n/a |
| STCube, Inc. · KRX:052020 | US$118.4M | US$72.43M | n/a | 13.6× | n/a | 2.6× | −338.7% | 0.0× | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Median of the others | US$122.7M | US$62.05M | 18.4× | 7.8× | 12.3× | 2.2× | −180.6% | 0.1× | 1.08 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.67 CAD · Analysts' mean
- EPS, year to Dec 2026
- -3.11 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director |
| Liz Williams | CFO |
| Caitlin Lowie | Vice President, Investor Relations & Communications |
| Antoinette Paone | Chief Development Officer and Head of Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Geoff MacKay | Chair, BOD | Chair, Compensation Committee |
| Adam Mostafa | Director | Chair, Audit Committee |
| Brian Bloom | Director |
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director |
| Franklin M. Berger | Director |
| Iris Loew-Friedrich | Director |
| Mark Nawacki | Director |
| Selwyn Ho | Director |
| Stephanie Brown | Director | Chair, Nominations and Governance Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −0.4% |
| Q2 2026 | Aug 13, 2026 · After close | −3.4% |
| Q1 2026 | May 13, 2026 · Before open | −2.2% |
| Q4 2025 | Mar 27, 2026 · Before open | −10.3% |
| Q3 2025 | Nov 14, 2025 · Before open | +5.8% |
| Q2 2025 | Aug 13, 2025 · Before open | −8.3% |
| Q1 2025 | May 13, 2025 · Before open | +4.7% |
| Q4 2024 | Mar 26, 2025 | +2.6% |
| Q3 2024 | Nov 13, 2024 · Before open | +1.2% |
| Q2 2024 | Aug 12, 2024 · After close | +4.3% |
All 14 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | 0.0% |
| Q4 2023 | Mar 27, 2024 · Before open | +4.3% |
| Q3 2023 | Nov 22, 2023 · After close | 0.0% |
| Q4 2022 | Mar 29, 2023 · After close | +24.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 17 slides | Nov 6, 2026 |
| Corporate Update (July 2026) | Corporate update | 14 slides | Jul 8, 2026 |
| 2026 Bloom Burton & Co. Healthcare Investor Conference | Conference | 23 slides | April 2026 |
| Technical Presentation (February 2026) | Technical | 52 slides | Feb 24, 2026 |
| Investor Presentation (February 2026) | Investor deck | 21 slides | February 2026 |
| Investor Presentation (October 2025) | Investor deck | 19 slides | October 2025 |
| Investor Presentation (June 2025) | Investor deck | 22 slides | Jun 5, 2025 |
| CureDuchenne FUTURES National Conference 2025 | Conference | 11 slides | May 24, 2025 |
| 2025 Bloom Burton & Co. Healthcare Investor Conference | Conference | 26 slides | May 5, 2025 |
| 30th Annual PPMD Conference 2024 | Conference | 12 slides | Jun 29, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 17 slides | February 2024 |
| Investor Presentation (February 2023) | Investor deck | 21 slides | February 2023 |
| Life Science Investor Forum 2022 | Conference | 17 slides | Jun 23, 2022 |
| Investor Day (March 2022) | Investor day | 16 slides | Mar 13, 2022 |
| Investor Presentation (February 2022) | Investor deck | 21 slides | Feb 22, 2022 |
| Market Radius (February 2022) | Conference | 19 slides | Feb 9, 2022 |
| Investor Presentation (December 2021) | Investor deck | 21 slides | December 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of common shares and pre-funded warrants Closed: US$57.2M raised · US$10.1 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Bloom Burton, Bloom Burton Securities Inc. Buyers: Franklin Berger (24,750 common shares); Mark Nawacki (30,000 common shares) Insiders: Director Franklin Berger purchased 24,750 common shares; no other insiders participated. Use of proceeds: Research and development including SAT-3247 clinical trials, other discovery and pre-clinical programs, working capital and general corporate purposes | Feb 9, 2026 | |
| Warrant exercise of share purchase warrants Closed: C$1.04M raised | Sep 22, 2025 | US$754,560 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 25.0K | |||||
| Cost of revenue | 5.09K | 7.00K | 3.73M | 165.7K | 422 | 3.06K | 1.54K | 23.5K | 27.4K | |
| Gross profit | -5.09K | -8.82M | -3.73M | -165.7K | -422 | -3.06K | -1.54K | -23.5K | -27.4K | |
| Research and development | 18.4M | 14.4M | 8.82M | 2.59M | 1.88M | 892.8K | 917.5K | 1.42M | 786.6K | 564.2K |
| Selling, general and administrative | 7.44M | 6.06M | 4.66M | 1.13M | 182.4K | 857.4K | ||||
| Operating income | -26.5M | -20.4M | -15.5M | -8.43M | -6.65M | -2.77M | -2.21M | -2.20M | -1.47M | -1.23M |
| Depreciation and amortization | 4.00K | 15.0K | 7.00K | 337.0K | 165.7K | 422 | 734 | 1.54K | 23.5K | 27.4K |
| EBITDA | -26.5M | -20.4M | -15.5M | -8.09M | -6.48M | -2.77M | -2.20M | -2.20M | -1.45M | -1.20M |
| Interest expense | 177.0K | 50.9K | 985.3K | 23.0K | ||||||
| Income before tax | -24.7M | -20.6M | -15.9M | -11.3M | -15.5M | -1.58M | -2.20M | -1.70M | -1.24M | -1.49M |
| Income tax | 172.0K | 177.0K | 5.00K | -42.4K | -270.6K | -264.8K | ||||
| Net income | -24.9M | -20.6M | -15.9M | -11.3M | -15.5M | -1.58M | -1.94M | -1.70M | -1.24M | -1.49M |
| Earnings per share, basic | -1.70 | -2.16 | -2.21 | -3.81 | -7.73 | -0.58 | -0.71 | -4.84 | -3.51 | -4.23 |
| Earnings per share, diluted | -1.70 | -2.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.80M | 40.1M | 22.1M | 1.92M | 4.87M | 717.5K | 399.1K | 10.1K | 1.13M | 2.36M |
| Short-term investments | 17.9M | 8.47M | 17.5M | 2.36M | ||||||
| Receivables | 369.3K | 583.0K | 260.4K | 528.0K | 409.1K | 12.5K | 129.7K | 88.4K | 37.1K | |
| Inventory | -583.0K | -260.0K | -528.0K | -409.1K | ||||||
| Current assets | 31.9M | 50.7M | 40.3M | 2.23M | 5.44M | 1.13M | 1.07M | 175.0K | 1.37M | 2.42M |
| Property, plant and equipment | 5.00K | 4.00K | 13.8K | 5.85K | ||||||
| Goodwill | -190 | |||||||||
| Total assets | 31.9M | 50.7M | 44.3M | 6.20M | 12.6M | 1.13M | 1.07M | 178.1K | 1.37M | 2.45M |
| Accounts payable | 4.11M | 3.58M | 1.04M | 1.47M | 1.13M | 128.5K | 629.2K | |||
| Current liabilities | 4.11M | 3.58M | 3.62M | 2.83M | 2.10M | 220.0K | 664.8K | 802.5K | 288.2K | 138.1K |
| Total debt | 1.09M | |||||||||
| Total liabilities | 4.11M | 3.58M | 3.62M | 2.83M | 2.10M | 1.31M | 664.8K | 802.5K | 288.2K | 138.1K |
| Shareholders' equity | 27.8M | 47.2M | 40.7M | 3.37M | 10.5M | -183.8K | 408.6K | -624.4K | 1.09M | 2.31M |
| Shares outstanding | 14.6M | 7.20M | 2.97M | 2.01M | 2.74M | 2.74M | 351.9K | 351.9K | 351.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.6M | -18.3M | -14.4M | -5.64M | -5.03M | -1.66M | -1.92M | -1.10M | -1.33M |
| Capital spending | -6.00K | -4.00K | -18.0K | -3.00K | -7.25K | 0 | -771 | -3.19K | -4.03K |
| Free cash flow | -23.6M | -18.3M | -14.5M | -5.79M | -5.04M | -1.66M | -1.93M | -1.11M | -1.34M |
| Cash from investing | -9.42M | 4.66M | -17.5M | -3.00K | 1.74M | -771 | -3.19K | -4.03K | |
| Cash from financing | 2.24M | 37.6M | 51.0M | 2.77M | 7.45M | 1.98M | 1.16M | ||
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 2.24M | 37.0M | 2.02M | ||||||
| Change in cash | -30.3M | 23.4M | 20.1M | -2.95M | 4.15M | 318.4K | -767.9K | -1.12M | -366.5K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
All 56 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 14, 2026 | Current report | SEC |
| SUPPL | Aug 14, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
| F-X | Aug 11, 2026 | Other filings | SEC |
| F-10 · Registration statement | Aug 11, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 25, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 20, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | May 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Apr 9, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| 40-F · Annual report | Mar 27, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 6, 2026 | Current report | SEC |
| SUPPL | Feb 6, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Feb 6, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2026 | Other filings | SEC |
| F-X | Feb 5, 2026 | Other filings | SEC |
| F-10 · Registration statement | Feb 5, 2026 | Offer document | SEC |
| D | Jan 3, 2025 | Other filings | SEC |
| D | May 25, 2023 | Other filings | SEC |
| D | Sep 27, 2022 | Other filings | SEC |
| D | Sep 10, 2019 | Other filings | SEC |
| D | Mar 8, 2019 | Other filings | SEC |
| D | Feb 5, 2014 | Other filings | SEC |
| D/A | Nov 21, 2013 | Other filings | SEC |
| D | Nov 15, 2011 | Other filings | SEC |
| D/A | Dec 1, 2009 | Other filings | SEC |
| D | Nov 6, 2009 | Other filings | SEC |
| REGDEX | Mar 25, 2009 | Other filings | SEC |
| REGDEX | Dec 19, 2007 | Other filings | SEC |
Cap table
Built by 6ix from Satellos Bioscience Inc’s releases · as of Feb 9, 2026
- Common shares
- 21,216,439
- Fully diluted
- 21,216,439
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 21,216,439 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 21,216,439 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Mostafa | Director | Chair, Audit Committee · Since at least Jun 18, 2025 |
| Antoinette Paone | Chief Development Officer and Head of Regulatory Affairs · Since at least Jan 29, 2026 |
| Brian Bloom | Director · Since at least Jun 18, 2025 |
| Caitlin Lowie | Vice President, Investor Relations & Communications · Since at least Oct 27, 2026 |
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director · Since at least Oct 5, 2026 |
| Franklin M. Berger | Director · Since at least Feb 9, 2026 |
| Geoff MacKay | Chair, BOD | Chair, Compensation Committee · Since at least Jun 18, 2025 |
| Iris Loew-Friedrich | Director · Since at least Jun 18, 2025 |
| Liz Williams | CFO · Since at least Mar 27, 2026 |
| Mark Nawacki | Director · Since at least Nov 14, 2025 |
All 13 people
| Person | Seat |
|---|---|
| Selwyn Ho | Director · Since at least Jun 18, 2025 |
| Stephanie Brown | Director | Chair, Nominations and Governance Committee · Since at least Jun 18, 2025 |
| Wildon Farwell | chief medical officer · Aug 13, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Satellos Bioscience Inc.